한글목차

본 보고서는 생물학적 제제 및 파이프라인 치료제의 사용에 초점을 맞추어 축성 척추관절염(axSpA) 치료의 현황과 향후 방향에 대해 상세하게 분석하였습니다. 비스테로이드성 항염증제(NSAIDs)에 이은 1차 선택약물로서 항종양괴사인자(TNF) 억제제의 사용, 코센틱스, 타르츠, 빔제렉스와 같은 인터루킨-17(IL-17) 억제제의 위치, 젤잔즈와 림보크와 같은 야누스 키나아제(JAK) 억제제의 axSpA 관리의 현재 치료 전략과 새로운 트렌드에 대한 종합적인 개요를 확인할 수 있습니다.

보고서 내용

• 현재 axSpA 치료에 항TNF가 어떻게 사용되고 있는가?
• 항TNF 바이오시밀러가 axSpA 치료에 미치는 영향은?
• Cosentyx, Taltz, Bimzelx 등 IL-17 억제제는 치료 알고리즘에서 어떤 위치를 차지하고 있는가?
• 장기 임상시험이 IL-17 처방 트렌드에 미친 영향은?
• Rinvoq, Xeljanz 등 JAK 억제제는 axSpA 치료 패러다임에서 어떤 위치를 차지하고 있는가?
• ORAL 감시 시험이 JAK 억제제 처방에 영향을 미쳤나?
• Jyseleca는 axSpA 시장에서 가능성이 있는가, 그리고 무엇을 보여주어야 하는가?
• axSPA 진단 및 치료의 현재 미충족 수요는?
• 향후 3-5년 동안 axSpa의 치료 알고리즘은 어떻게 발전할 것인가?

주요 브랜드

영문목차

This report provides an in-depth analysis of the current landscape and future directions in the treatment of axial spondyloarthritis (axSpA), focusing on the use of biologic and pipeline therapies. It examines the use of anti-tumour necrosis factor (TNF) inhibitors as the first-line treatment following non-steroidal anti-inflammatory drugs (NSAIDs), the positioning of interleukin-17 (IL-17) inhibitors, such as Cosentyx, Taltz, and Bimzelx, and the cautious use of Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq. Gain a comprehensive overview of current treatment strategies and emerging trends in axSpA management.

Key Questions Answered:

• How are anti-TNFs currently used in axSpA treatment lines?
• What impact have anti-TNF biosimilars had on axSpA treatment?
• How are IL-17 inhibitors like Cosentyx, Taltz, and Bimzelx positioned in treatment algorithm?
• How have long-term trials influenced IL-17 prescription trends?
• Where do JAK inhibitors like Rinvoq and Xeljanz fit in the axSpA treatment paradigm?
• Has the ORAL Surveillance study affected JAK inhibitor prescriptions?
• Does Jyseleca have potential in the axSpA market, and what must it demonstrate?
• What are the current unmet needs in axSpA diagnosis and treatment?
• How will the axSpA treatment algorithm evolve over the next three to five years?

Key Brands:

Partial List of Participating Experts:

• Associate Professor of Medicine, Director of Yale Spondyloarthritis Program and Co-chair, Safety and Quality Council at Yale School of Medicine, CT
• Assistant Professor of Medicine, Brigham and Women's Hospital, MA
• Clinical Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
• Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
• Full Professor of Rheumatology at the Department of Medicine and Health Sciences "Vincenzo Tiberio" and Head of the Internal Medicine and Rheumatology Unit at the University of Molise in Campobasso, Italy
• Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and Immunology Center ARC in Amsterdam, Netherlands

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.